Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)‘s stock had its “outperform” rating reaffirmed by equities research analysts at JMP Securities in a report issued on Tuesday. They currently have a $11.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $5.00. JMP Securities’ target price points to a potential upside of 165.06% from the company’s current price.

Separately, ValuEngine downgraded Marinus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, July 7th.

Shares of Marinus Pharmaceuticals (NASDAQ MRNS) opened at 4.15 on Tuesday. The company’s 50-day moving average price is $2.53 and its 200-day moving average price is $1.68. Marinus Pharmaceuticals has a 12-month low of $0.82 and a 12-month high of $5.44. The firm’s market capitalization is $108.21 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.06. Analysts anticipate that Marinus Pharmaceuticals will post ($0.76) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “JMP Securities Reiterates “Outperform” Rating for Marinus Pharmaceuticals, Inc. (MRNS)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/12/jmp-securities-reiterates-outperform-rating-for-marinus-pharmaceuticals-inc-mrns.html.

Institutional investors have recently modified their holdings of the business. KCG Holdings Inc. grew its holdings in Marinus Pharmaceuticals by 29.5% during the 1st quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 14,692 shares during the period. Granite Point Capital Management L.P. acquired a new stake in Marinus Pharmaceuticals during the 1st quarter worth about $1,372,000. Nexthera Capital LP acquired a new stake in Marinus Pharmaceuticals during the 1st quarter worth about $1,416,000. Finally, Jennison Associates LLC grew its holdings in Marinus Pharmaceuticals by 108.1% during the 2nd quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock worth $1,112,000 after acquiring an additional 421,600 shares during the period. Hedge funds and other institutional investors own 28.76% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Stock Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.